Fastin

Caloric Restriction, Obesity, Type 2 Diabetes + 6 more

Treatment

3 FDA approvals

20 Active Studies for Fastin

What is Fastin

Phentermine

The Generic name of this drug

Treatment Summary

Phentermine is a drug used to control weight, and it was first introduced in 1959. It is related to, but not as strong as amphetamines and is classified as a Schedule IV drug, meaning it has a low potential for abuse. Phentermine was initially available as part of a combination drug with other medications, but later it was approved on its own. In 2012, a new combination of phentermine with topiramate was approved, which requires lower doses of phentermine to be effective.

Ionamin

is the brand name

image of different drug pills on a surface

Fastin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ionamin

Phentermine

1959

298

Approved as Treatment by the FDA

Phentermine, also known as Ionamin, is approved by the FDA for 3 uses including Obesity and Comorbidity .

Obesity

Used to treat Obesity in combination with Topiramate

Comorbidity

Used to treat one related comorbidity in combination with Topiramate

Regime of weight reduction

Effectiveness

How Fastin Affects Patients

Phentermine works by suppressing appetite and increasing the amount of energy the body uses while resting. Clinical studies show that people taking phentermine lose an average of 3.6 kilograms in 2-24 weeks compared to those taking a placebo. Even after treatment ends, patients tend to keep the weight off. Phentermine is related to amphetamines, but does not have any of the same stimulating or dangerous effects, like high blood pressure or an irregular heartbeat.

How Fastin works in the body

Phentermine works by increasing the amount of a chemical called noradrenaline in the brain. Noradrenaline is a kind of hormone that triggers a “fight or flight” response, which suppresses the feeling of hunger and reduces the need for energy. It also has an indirect effect on serotonin, another hormone that helps regulate appetite. Additionally, it is thought that phentermine may inhibit a chemical called neuropeptide Y, which is involved in hunger signals. Finally, it is a weak inhibitor of monoamine oxidase, which may contribute to its effects.

When to interrupt dosage

The recommended dosage of Fastin hinges on the diagnosed circumstance, including Regime of weight reduction, Hyperlipidemia and Type 2 Diabetes. The measure of dosage is contingent upon the technique of administration (e.g. Oral or Tablet) mentioned in the table underneath.

Condition

Dosage

Administration

Obesity

, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg

Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet - Oral, Tablet, Capsule, extended release

Caloric Restriction

, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg

Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet - Oral, Tablet, Capsule, extended release

Type 2 Diabetes

, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg

Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet - Oral, Tablet, Capsule, extended release

Hypertensive disease

, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg

Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet - Oral, Tablet, Capsule, extended release

High Cholesterol

, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg

Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet - Oral, Tablet, Capsule, extended release

Regime of weight reduction

, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg

Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet - Oral, Tablet, Capsule, extended release

Chronic Weight Management therapy

, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg

Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet - Oral, Tablet, Capsule, extended release

increase in physical activity

, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg

Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet - Oral, Tablet, Capsule, extended release

Comorbidity

, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg

Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet - Oral, Tablet, Capsule, extended release

Warnings

Fastin Contraindications

Condition

Risk Level

Notes

Hyperthyroidism

Do Not Combine

concomitant use or 14 days after discontinuation

Do Not Combine

Agitation

Do Not Combine

Drug abuse

Do Not Combine

Cardiovascular Diseases

Do Not Combine

Open-angle glaucoma

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Phentermine may interact with Pulse Frequency

There are 20 known major drug interactions with Fastin.

Common Fastin Drug Interactions

Drug Name

Risk Level

Description

Iobenguane

Major

Phentermine can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.

Methylene blue

Major

Phentermine may increase the serotonergic activities of Methylene blue.

Mirtazapine

Major

Phentermine may increase the serotonergic activities of Mirtazapine.

1-benzylimidazole

Minor

The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Phentermine.

4-Methoxyamphetamine

Minor

The risk or severity of hypertension can be increased when Phentermine is combined with 4-Methoxyamphetamine.

Fastin Toxicity & Overdose Risk

The toxic dose of phentermine in rats is reported to be 151 mg/kg. Overdosing on this drug can cause restlessness, tremors, confusion, hallucinations, fatigue, depression, fast heartbeat, arrhythmias, high or low blood pressure, nausea, vomiting, diarrhea, abdominal cramps, skin problems, insomnia, irritability, hyperactivity, and changes in personality. In severe cases, this can lead to a psychosis-like state. Studies have not been done to determine if phentermine causes cancer or mutations.

image of a doctor in a lab doing drug, clinical research

Fastin Novel Uses: Which Conditions Have a Clinical Trial Featuring Fastin?

104 active clinical trials are currently being conducted to assess the value of Fastin in the management of Type 2 Diabetes, Weight Loss Regime and Disease.

Condition

Clinical Trials

Trial Phases

Type 2 Diabetes

96 Actively Recruiting

Not Applicable, Phase 2, Phase 3, Phase 4, Phase 1, Early Phase 1

Obesity

0 Actively Recruiting

Hypertensive disease

0 Actively Recruiting

Comorbidity

0 Actively Recruiting

High Cholesterol

15 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Early Phase 1

Caloric Restriction

0 Actively Recruiting

Regime of weight reduction

0 Actively Recruiting

increase in physical activity

0 Actively Recruiting

Chronic Weight Management therapy

0 Actively Recruiting

Fastin Reviews: What are patients saying about Fastin?

5

Patient Review

6/6/2010

Fastin for Overweight

I had way more energy and didn't crave food as much. I lost 36 pounds in 3 months, but gained it all back after stopping the treatment. It's really effective, but made me dizzy and not want to eat at first.

5

Patient Review

6/17/2011

Fastin for Overweight

I do not recommend this drug, especially for those who are under the age of 18. I experienced an abnormal heart rate, shakes, and hallucinations.

5

Patient Review

9/1/2010

Fastin for Overweight

I initially lost 75 pounds and have been able to keep off 60 of those pounds for over a year now.

5

Patient Review

2/23/2011

Fastin for Overweight

This treatment has helped me a lot. I feel much more motivated and clearheaded now.

5

Patient Review

8/9/2009

Fastin for Overweight

5

Patient Review

9/10/2009

Fastin for Overweight

5

Patient Review

9/10/2009

Fastin for Overweight

5

Patient Review

10/15/2009

Fastin for Overweight

4.7

Patient Review

12/17/2009

Fastin for Overweight

I have been on fasten for two weeks- already lost 8 pounds with no noticeable side effects (just a little dry mouth, but that's easy to fix with water). This drug is wonderful- my goal is to lose 50 pounds and I'm confident that I'll reach it. I also used to have CFS but not anymore! I can stay awake to watch a movie now, which makes me so happy.

4.7

Patient Review

2/13/2010

Fastin for Overweight

I started taking this medication at the end of August and have since lost 30 pounds. I've been feeling really energetic and motivated to exercise, which has been great!

4.3

Patient Review

6/22/2011

Fastin for Overweight

I haven't been taking this pill every day as recommended because I get really hungry when I do. Even just taking it 2-3 days in a row makes me ravenous. There are no side effects that I've noticed, which is great, but the hunger is hard to manage. So far I've only been taking it 3 days a week and eating fruit during the day, plus a meal when I get home. In three weeks I've lost at least 8lbs. Does anyone have any suggestions or know if it would work better if taken everyday?

4

Patient Review

8/6/2009

Fastin for Overweight

3.7

Patient Review

11/17/2011

Fastin for Overweight

This medication was effective in reducing my appetite. However, I also experienced an embarrassing side effect that I have not seen listed anywhere else: an inability to urinate. This happened regardless of how much fluids I consumed or how long I waited. If anyone else has had this problem, please let me know.

2.7

Patient Review

5/29/2010

Fastin for Overweight

I saw the best results when I remembered to take this medication on an empty stomach, though after a few months the effectiveness decreased. The time-released capsules were especially helpful.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about fastin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is phentermine and fastin the same thing?

"Phentermine is an appetite suppressant that is used as a short-term weight loss aid.

The drug Fastin was once a brand name of phentermine, which was manufactured by King Pharmaceuticals. Phentermine is an appetite suppressant that is used to help with short-term weight loss."

Answered by AI

What does fastin mean?

"It is called "diet pills" because it makes dieting easier by suppressing the appetite.

Amphetamines and other psychoactive drugs that help with weight loss by suppressing appetite are colloquially known as "diet pills.""

Answered by AI

What are fastin pills?

"An prescription medication, Fastin, is available to help treat Obesity. Fastin can be used by itself or in combination with other drugs. Classified as a CNS Stimulant, Anorexiant, and Stimulant, Fastin works by affecting the levels of certain neurotransmitters in the brain."

Answered by AI

Is the drug fastin still available?

"Fastin, a brand name drug, is no longer available in the United States. The generic version of the drug is still available, however."

Answered by AI

Clinical Trials for Fastin

Image of Weill Cornell Medicine in New York, United States.

Coronary Artery Calcium Testing for Cardiovascular Disease

18+
All Sexes
New York, NY

The goal of this study is to improve how primary care providers identify and manage patients at risk for heart disease. One tool that can help with this is a coronary artery calcium (CAC) test, which looks for calcium buildup in the heart's arteries and can help estimate a person's risk of future heart problems. The main questions this study aims to answer are: Will a new electronic health record (EHR) alert that provides guidance on when to consider a CAC test be feasible and acceptable to primary care providers? Does the alert change how often providers order CAC tests, start or change the dose of cholesterol-lowering medications, and refer patients to cardiology? In this study, a new EHR alert will be implemented as part of routine clinical practice for primary care providers at Weill Cornell Internal Medicine Associates (WCIMA). The alert will provide guidance on considering a CAC test, cholesterol-lowering medication, or referral to cardiology for eligible patients. Researchers will compare clinical care before and after the alert is implemented. They will look at how often CAC tests are ordered and completed, how often cholesterol-lowering medications are started or their doses are changed, and how often patients are referred to cardiology. After the implementation period, primary care providers will also be asked to complete a brief survey and participate in an interview about the alert.

Waitlist Available
Has No Placebo

Weill Cornell Medicine

Madeline R Sterling, MD, MPH

Merck Sharp & Dohme LLC

Have you considered Fastin clinical trials?

We made a collection of clinical trials featuring Fastin, we think they might fit your search criteria.
Go to Trials
Image of University of Alberta Hospital / Mazankowski Alberta Heart Institute in Edmonton, Canada.

Pharmacist-Led Lipid Optimization for High Cholesterol

Any Age
All Sexes
Edmonton, Canada

The purpose of this study is to determine whether a proactive, EHR-guided approach helps more individuals reach safe cholesterol levels, improves medication use, and reduces future heart attacks and strokes, compared to usual care. The main question it aims to answer is: • Does the EHR-LOCALE pathway increases the proportion of patients who reach the LDL-cholesterol target of \<1.8 mmol/L at 6 months? Participants in the interventional group receive: * Pharmacist contact * Repeat lipid requisitions * Review of medications, adherence, and side effects * Treatment escalation according to national dyslipidemia guidelines

Recruiting
Has No Placebo

University of Alberta Hospital / Mazankowski Alberta Heart Institute

Pishoy Gouda, MD

Image of University of Michigan in Ann Arbor, United States.

Supportive Interventions for Diabetes

18+
All Sexes
Ann Arbor, MI

Unmet social needs and economic burden persist as key reasons why one-third of people with diabetes have poor disease control. The purpose of this study is to learn whether different tools and types of support may help people manage diabetes and related challenges. The study will compare several approaches to understand how they affect people's experiences and health over time. Completion of the study aims will lead to an optimized intervention to improve the health and social well-being of people with diabetes. Participants will be randomly assigned to one or more interventions aimed at addressing social and financial needs and will complete multiple surveys over the course of a year. The study team will collect information about their blood pressure and HbA1c (blood glucose). Findings will advance the field by determining the effectiveness of supportive interventions to address both social needs and diabetes self-care, and by informing protocols for the optimal sequencing of these strategies, a critical evidence gap in healthcare settings.

Recruiting
Has No Placebo

University of Michigan

Have you considered Fastin clinical trials?

We made a collection of clinical trials featuring Fastin, we think they might fit your search criteria.
Go to Trials
Image of University of Texas Southwestern Medical Center in Dallas, United States.

Low-dose Colchicine for Chronic Kidney Disease

18 - 69
All Sexes
Dallas, TX

The overall objective of this pilot randomized clinical trial is to determine whether low-dose Colchicine (LoDoCo) improves vascular disease including vascular calcification, peripheral arterial disease (PAD), and chronic kidney disease-mineral and bone disorder (CKD-MBD) biomarkers in patients with chronic kidney disease (CKD) stage 3 over a 12-month intervention period, compared with usual care. Successful completion of this study will generate critical preliminary data to support a larger clinical trial aimed at evaluating inflammation-targeted therapies to mitigate CKD-MBD, including vascular calcification and related PAD, as well as osteoporosis, ultimately reducing cardiovascular events and mortality in patients with CKD. Additionally, this work has the potential to redefine the diagnostic framework for CKD-MBD.

Phase 2
Waitlist Available

University of Texas Southwestern Medical Center

Jing Chen, MD

Image of Cleveland Clinic Foundation in Cleveland, United States.

Capsule Endoscopy for Bariatric Surgery Candidates

18+
All Sexes
Cleveland, OH

The goal of this clinical trial is to test if a swallowable camera capsule can safely examine the upper digestive tract in people preparing for weight loss surgery. The camera capsule (called NaviCam® Xpress™ Stomach System) is controlled by magnets from outside the body and doesn't require sedation, unlike traditional endoscopy. The main questions it aims to answer are: Can the camera capsule be safely used in people with a body mass index (BMI) greater than 38? Can doctors successfully control and move the camera capsule to see the necessary areas of the stomach and esophagus? Researchers will evaluate 30 participants who are preparing for weight loss surgery. Participants will: Swallow the camera capsule with water after not eating or drinking since midnight Have their upper digestive tract examined while the doctor controls the capsule from outside their body Complete a brief satisfaction survey about their experience Be followed up with a phone call 2-3 weeks after the procedure This study could help determine if the camera capsule is a good alternative to traditional endoscopy for people preparing for weight loss surgery, potentially avoiding the need for sedation.

Waitlist Available
Has No Placebo

Cleveland Clinic Foundation

Jerry Dang, MD, PhD

AnX Robotica Corp.

Image of University of Southern California in Los Angeles, United States.

Antibiotics for Diabetes with Bone Fractures

18+
All Sexes
Los Angeles, CA

The goal of this clinical trial is to learn if taking an antibiotic pill for 7 days after surgery reduces the risk of wound infection in adults with poorly controlled diabetes who have surgery to fix a broken bone in the leg, ankle, or foot. It will also learn about the safety of the extended antibiotic course. The main questions it aims to answer are: Does a 7-day antibiotic course after surgery lower the rate of wound infection within 90 days? What medical problems do participants have when taking the extended antibiotic course? Researchers will compare a 7-day course of an oral antibiotic (cefadroxil) to standard care (no additional antibiotics after surgery) to see if the extended course reduces infections. Participants will: Take an antibiotic pill or receive standard care for 7 days after surgery Receive a phone call from the study team about 1 week after surgery Visit the clinic at 3 weeks, 6 weeks, and 3 months after surgery for checkups

Phase 4
Recruiting

University of Southern California (+2 Sites)

Image of University of Missouri-Kansas City in Kansas City, United States.

Enhanced Diabetes Prevention Program for Prediabetes

18+
All Sexes
Kansas City, MO

The goal of this clinical trial is to learn if an enhanced, culturally, socially, and structurally tailored Diabetes Prevention Program (E-DPP) can improve weight loss and related diabetes risk factors in African American adults with prediabetes living in low-income, socially vulnerable communities. The main questions it aims to answer are: * Does the enhanced DPP (E-DPP) lead to greater percent weight loss at 6 and 12 months compared to the standard culturally tailored DPP (S-DPP)? * How do social determinants (e.g., food insecurity, stigma, access to resources) influence weight loss and engagement in lifestyle behaviors? Researchers will compare a standard culturally tailored DPP (S-DPP) to an enhanced DPP (E-DPP) to see if improving access to healthy food, physical activity, and community resources increases weight loss and improves diabetes-related outcomes. Participants will 1. Attend DPP sessions delivered in community settings (e.g., churches) 2. Receive lifestyle education focused on diet, physical activity, and weight loss 3. Engage in physical activity (including in-class exercise sessions \[E-DPP only\] and community-based options) 4. Receive support for healthy eating, including food deliveries (\[E-DPP only\]), food selection guidance, and referrals to food assistance programs 5. Receive information and support for accessing community resources for food and physical activity

Waitlist Available
Has No Placebo

University of Missouri-Kansas City

Jenifer E Jenifer, PhD

Have you considered Fastin clinical trials?

We made a collection of clinical trials featuring Fastin, we think they might fit your search criteria.
Go to Trials